Advances in delivery vectors for gene therapy in liver cancer

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death globally, mainly due to lack of effective treatments – a problem that gene therapy is poised to solve. Successful gene therapy requires safe and efficient delivery vectors, and recent advances in both viral and nonviral ve...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic delivery 2020-01, Vol.11 (1), p.833-850
Main Authors: Redd Bowman, Katherine E, Lu, Phong, Vander Mause, Erica R, Lim, Carol S
Format: Article
Language:English
Subjects:
CRISPR
exosomes
gene delivery
gene editing
gene therapy
hepatocellular carcinoma
nanoparticles
viral vectors
virosomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the third most common cause of cancer death globally, mainly due to lack of effective treatments – a problem that gene therapy is poised to solve. Successful gene therapy requires safe and efficient delivery vectors, and recent advances in both viral and nonviral vectors have made an important impact on HCC gene therapy delivery. This review explores how adenoviral, retroviral and adeno-associated viral vectors have been modified to increase safety and delivery capacity, highlighting studies and clinical trials using these vectors for HCC gene therapy. Nanoparticles, liposomes, exosomes and virosomes are also featured in their roles as HCC gene delivery vectors. Finally, new discoveries in gene editing technology and their impacts on HCC gene therapy are discussed.
ISSN:2041-5990
2041-6008
DOI:10.4155/tde-2019-0076